Genocea Biosciences (NASDAQ:GNCA) Price Target Lowered to $3.00 at Robert W. Baird

Genocea Biosciences (NASDAQ:GNCAGet Rating) had its price target dropped by stock analysts at Robert W. Baird from $8.00 to $3.00 in a note issued to investors on Monday, The Fly reports.

Separately, StockNews.com began coverage on Genocea Biosciences in a research report on Monday. They set a “sell” rating on the stock.

Genocea Biosciences stock opened at $0.40 on Monday. The firm has a market cap of $23.49 million, a price-to-earnings ratio of -0.66 and a beta of 1.45. Genocea Biosciences has a 52 week low of $0.39 and a 52 week high of $2.90. The business’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.31. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.15.

Genocea Biosciences (NASDAQ:GNCAGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). During the same period in the prior year, the firm posted ($0.18) earnings per share. Equities analysts expect that Genocea Biosciences will post -0.76 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GNCA. State Street Corp purchased a new position in shares of Genocea Biosciences in the second quarter valued at approximately $46,000. Morgan Stanley boosted its position in shares of Genocea Biosciences by 197.5% during the 2nd quarter. Morgan Stanley now owns 16,504 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 10,957 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Genocea Biosciences by 9.2% in the second quarter. Millennium Management LLC now owns 286,041 shares of the biotechnology company’s stock valued at $669,000 after purchasing an additional 24,185 shares during the period. Geode Capital Management LLC grew its holdings in shares of Genocea Biosciences by 3.5% in the third quarter. Geode Capital Management LLC now owns 185,942 shares of the biotechnology company’s stock valued at $357,000 after purchasing an additional 6,228 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in shares of Genocea Biosciences by 6.1% in the third quarter. Point72 Asset Management L.P. now owns 2,652,974 shares of the biotechnology company’s stock valued at $5,094,000 after purchasing an additional 152,974 shares during the period. Institutional investors and hedge funds own 59.25% of the company’s stock.

About Genocea Biosciences (Get Rating)

Genocea Biosciences, Inc engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes and GEN-009, a neoantigen cancer vaccine.

See Also

The Fly logo

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.